Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 230Squamous Cell Carcinoma of Head and Neck 139Head and Neck Neoplasms 131Lung Neoplasms 117Esophageal Neoplasms 88Stomach Neoplasms 84Uterine Cervical Neoplasms 68Esophageal Squamous Cell Carcinoma 66Urinary Bladder Neoplasms 59Breast Neoplasms 55Nasopharyngeal Carcinoma 51Small Cell Lung Carcinoma 46Carcinoma, Squamous Cell 39Neoplasm Metastasis 38Pancreatic Neoplasms 36Neoplasms 35Biliary Tract Neoplasms 34Oropharyngeal Neoplasms 32Cholangiocarcinoma 32Ovarian Neoplasms 30Mesothelioma, Malignant 28Adenocarcinoma Of Esophagus 28Lymphoma 25Carcinoma 24Adenocarcinoma of Lung 24Central Nervous System Neoplasms 22Laryngeal Neoplasms 20Carcinoma, Ovarian Epithelial 20Recurrence 19Lymphoma, Large B-Cell, Diffuse 19

Interventions

durvalumab 1Gemcitabine 1Cisplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Resectable Biliary Tract Cancer × Cisplatin × Clear all
NCT05640791 2022-12-07

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
40 enrolled
Gastrointestinal

Resectable Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡